75 related articles for article (PubMed ID: 29680665)
1. Synthesis, biophysical characterization, and anti-HIV-1 fusion activity of DNA helix-based inhibitors with a p-benzyloxyphenyl substituent at the 5'-nucleobase site.
Tang Y; Han Z; Guo J; Tian Y; Liu K; Xu L
Bioorg Med Chem Lett; 2018 Jun; 28(10):1842-1845. PubMed ID: 29680665
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Biophysical Characterization, and Anti-HIV-1 Fusion Activity of DNA Quadruplex-based Inhibitors with Dipeptide MT Hook Conjugation.
Xu L; Han Z; Ren H
Curr HIV Res; 2021; 19(4):317-323. PubMed ID: 33902414
[TBL] [Abstract][Full Text] [Related]
4. A novel multivalent DNA helix-based inhibitor showed enhanced anti-HIV-1 fusion activity.
Tang Y; Han Z; Ren H; Guo J; Chong H; Tian Y; Liu K; Xu L
Eur J Pharm Sci; 2018 Dec; 125():244-253. PubMed ID: 30292749
[TBL] [Abstract][Full Text] [Related]
5. DNA Quadruplex-Based Inhibitor With Flexible Fragments at the 3' Terminal Shows Enhanced Anti-HIV-1 Fusion Activity.
Han Z; Tang Y; Ren H; Liu K; Xu L
J Pharm Sci; 2019 Jul; 108(7):2243-2246. PubMed ID: 30797782
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
Yang J; Li LL; Li JR; Yang JX; Zhang F; Chen G; Yu R; Ouyang WJ; Wu SW
Bioorg Med Chem Lett; 2018 Jan; 28(1):49-52. PubMed ID: 29162455
[TBL] [Abstract][Full Text] [Related]
7. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
Sánchez-Martín MJ; Urbán P; Pujol M; Haro I; Alsina MA; Busquets MA
Chemphyschem; 2011 Oct; 12(15):2816-22. PubMed ID: 21905195
[TBL] [Abstract][Full Text] [Related]
8. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
9. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
10. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
11. Enhanced potency of bivalent small molecule gp41 inhibitors.
Sofiyev V; Kaur H; Snyder BA; Hogan PA; Ptak RG; Hwang P; Gochin M
Bioorg Med Chem; 2017 Jan; 25(1):408-420. PubMed ID: 27908751
[TBL] [Abstract][Full Text] [Related]
12. The use of hairpin DNA duplexes as HIV-1 fusion inhibitors: synthesis, characterization, and activity evaluation.
Xu L; Jiang X; Xu X; Zheng B; Chen X; Zhang T; Gao F; Cai L; Cheng M; Keliang Liu
Eur J Med Chem; 2014 Jul; 82():341-6. PubMed ID: 24927054
[TBL] [Abstract][Full Text] [Related]
13. d(TGGGAG) with 5'-nucleobase-attached large hydrophobic groups as potent inhibitors for HIV-1 envelop proteins mediated cell-cell fusion.
Chen W; Xu L; Cai L; Zheng B; Wang K; He J; Liu K
Bioorg Med Chem Lett; 2011 Oct; 21(19):5762-4. PubMed ID: 21873060
[TBL] [Abstract][Full Text] [Related]
14. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
[TBL] [Abstract][Full Text] [Related]
15. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
[TBL] [Abstract][Full Text] [Related]
16. Development of potent and long-acting HIV-1 fusion inhibitors.
Chong H; Wu X; Su Y; He Y
AIDS; 2016 May; 30(8):1187-96. PubMed ID: 26919736
[TBL] [Abstract][Full Text] [Related]
17. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
18. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.
Zhou G; Wu D; Hermel E; Balogh E; Gochin M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1500-3. PubMed ID: 20153190
[TBL] [Abstract][Full Text] [Related]
20. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
Cai L; Jiang S
ChemMedChem; 2010 Nov; 5(11):1813-24. PubMed ID: 20845360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
